Risk factor
Very poor trading liquidity
Profitability factor
Very favourable analyst view
About
Paxman AB (publ), together with its subsidiaries, develops and sells Paxman scalp cooling system to minimize hair loss in connection with chemotherapy treatment in Europe, the United States, Mexico, Japan, Oceania, rest of Asia, and South and Central America. It serves various cancer centers and hospitals. The comapny has a research collaboration agreement with National...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of PAX.ST is 103 and suggests 119% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell